ABC | Volume 111, Nº2, Agosto 2018

Diretrizes 3ª Diretriz Brasileira de Transplante Cardíaco Arq Bras Cardiol. 2018; 111(2):230-289 100. Segovia J, Cosio MD, Barcelo JM, Bueno MG, Pavía PG, Burgos R, et al. RADIAL: a novel primary graft failure risk score in heart transplantation. J Heart Lung Transplant. 2011;30(6):644-51. doi: 10.1016/j.healun.2011.01.721. 101. Cosío-CarmenaMD, Gómez BuenoM, Almenar L, Delgado JF, Arizón JM, González Vilchez F, et al. Primary graft failure after heart transplantation: characteristics in a contemporary cohort and performance of the RADIAL risk score. J Heart Lung Transplant. 2013;32(12):1187-95. doi: 10.1016/j. healun.2013.08.004. 102. Boccheciampe N, Audibert G, Rangeard O, Charpentier C, Perrier JF, Lalot JM, et al. Serum troponin Ic values in organ donors are related to donor myocardial dysfunction but not to graft dysfunction or rejection in the recipients. Int J Cardiol. 2009;133(1):80-6. doi: 10.1016/j. ijcard.2007.12.006. 103. Khush KK, Menza RL, Babcock WD, Zaroff JG. Donor cardiac troponin I levels do not predict recipient survival after cardiac transplantation. J Heart Lung Transplant. 2007;26(10):1048-53. doi: 10.1016/j. healun.2007.07.026. 104. Potapov EV, Ivanitskaia EA, Loebe M, Möckel M, Müller C, Sodian R, et al. Value of cardiac troponin I and T for selection of heart donors and as predictors of early graft failure. Transplantation. 2001;71(10):1394-400. PMID: 11391225. 105. Vorlat A, Conraads VM, Jorens PG, Aerts S, Van Gorp S, Vermeulen T, et al. Donor B-type natriuretic peptide predicts early cardiac performance after heart transplantation. J Heart Lung Transplant. 2012;31(6):579-84. doi: 10.1016/j.healun.2012.02.009. 106. Birks EJ, Burton PB, Owen V, Mullen AJ, Hunt D, Banner NR, et al. Elevated tumor necrosis factor- alpha and interleukin-6 inmyocardium and serum of malfunctioning donor hearts. Circulation. 2000;102(19 Suppl 3):III352- 8. PMID: 11082413. 107. Wagner FD, Jonitz B, Potapov EV, Qedra N, Wegscheider K, Abraham K, et al. Procalcitonin, a donor- specific predictor of early graft failure- related mortality after heart transplantation. Circulation. 2001;104(12 Suppl1):I192-6. PMID: 11568054. 108. Aharinejad S, Andrukhova O, Gmeiner M, Thomas A, Aliabadi A, Zuckermann A, et al. Donor serum SMARCAL1 concentrations predict primary graft dysfunction in cardiac transplantation. Circulation. 2009;120(11 Suppl):S198-205. doi: 10.1161/ CIRCULATIONAHA.108.842971. 109. Nicolas-Robin A, Salvi N, Medimagh S, Amour J, LeManach Y, Coriat P, et al. Combined measurements of N-terminal pro-brain natriuretic peptide and cardiac troponins in potential organ donors. Intensive Care Med. 2007;33(6):986-92. doi: 10.1007/s00134-007-0601-7. 110. Potapov EV, Wagner FD, Loebe M, Ivanitskaia EA, Müller C, Sodian R, et al. Elevated donor cardiac troponin T and procalcitonin indicate two independent mechanisms of early graft failure after heart transplantation. Int J Cardiol. 2003;92(2-3):163-7. PMID: 14659848. 111. ArdehaliA,EsmailianF,DengM,SolteszE,HsichE,NakaY,etal;PROCEED II trial investigators. Ex-vivo perfusion of donor hearts for human heart transplantation (PROCEED II): a prospective, open-label, multicentre, randomised non-inferiority trial. Lancet. 2015;385(9987):2577-84. doi: 10.1016/S0140-6736(15)60261-6. 112. D’Alessandro C, Golmard JL, Barreda E, Laali M, Makris R, Luyt CE, et al. Predictive risk factors for primary graft failure requiring temporary extra- corporeal membrane oxygenation support after cardiac transplantation in adults. Eur J Cardiothorac Surg. 2011;40(4):962-9. doi: 10.1016/j. ejcts.2011.01.064. 113. Taghavi S, Zuckermann A, Ankersmit J, Wieselthaler G, Rajek A, Laufer G, et al. Extracorporeal membrane oxygenation is superior to right ventricular assist device for acute right ventricular failure after heart transplantation. Ann Thorac Surg. 2004;78(5):1644-9. doi: 10.1016/j. athoracsur.2004.04.059. 114. ThomasHL,DronavalliVB,ParameshwarJ,BonserRS,BannerNR;Steering Group of theUKCardiothoracic Transplant Audit. Incidence and outcome of Levitronix CentriMag support as rescue therapy for early cardiac allograft failure: aUnited Kingdomnational study. Eur J Cardiothorac Surg. 2011;40(6):1348-54. doi: 10.1016/j.ejcts.2011.02.045. 115. Rosenberg PB, Vriesendorp AE, Drazner MH, Dries DL, Kaiser PA, Hynan LS, et al. Induction therapy with basiliximab allows delayed initiation of cyclosporine and preserves renal function after cardiac transplantation. J Heart Lung Transplant. 2005;24(9):1327-31. doi: 10.1016/j.healun.2004.08.003. 116. Mehra MR, Zucker MJ, Wagoner L, Michler R, Boehmer J, Kovarik J, et al. A multicenter, prospective, randomized double-blind trial of basiliximab in heart transplantation. J Heart Lung Transplant. 2005;24(9):1297-304. doi: 10.1016/j.healun.2004.09.010. 117. Stehlik J, Edwards LB, Kucheryavaya AY, Benden C, Christie JD, Dipchand AI, et al; International Society of Heart and Lung Transplantation. The Registry of the International Society for Heart and Lung Transplantation: 29th official adult heart transplant report--2012. J Heart Lung Transplant. 2012;31(10):1052-64. doi: 10.1016/j.healun.2012.08.002. 118. Hershberger RE, Starling RC, Eisen HJ, Bergh CH, Kormos RL, Love RB, et al. Daclizumab to prevent rejection after cardiac transplantation. N Engl J Med. 2005;352(26):2705-13. doi: 10.1056/NEJMoa032953. 119. Teuteberg JJ,ShulloMA,ZomakR,ToyodaY,McNamaraDM,BermudezC, et al. Alemtuzumab induction prior to cardiac transplantation with lower intensity maintenance immunosuppression: one-year outcomes. Am J Transplant. 2010;10(2):382-8. doi: 10.1111/j.1600-6143.2009.02856.x 120. Segovia J, Rodríguez-Lambert JL, Crespo-Leiro MG, Almenar L, Roig E, Gómez-Sánchez MA, et al. A randomized multicenter comparison of basiliximab and muromonab (OKT3) in heart transplantation: SIMCOR study. Transplantation. 2006;81(11):1542-8. doi: 10.1097/01. tp.0000209924.00229.e5. 121. Lund LH, Edwards LB, Kucheryavaya AY, Benden C, Dipchand AI, Goldfarb S, et al. The Registry of the International Society for Heart and Lung Transplantation: Thirty-second Official Adult Heart Transplantation Report--2015; Focus Theme: Early Graft Failure. J Heart Lung Transplant. 2015;34(10):1244-54. doi: 10.1016/j.healun.2015.08.003. 122. Miller LW, Wolford T, McBride LR, Peigh P, Pennington DG. Successful withdrawal of corticosteroids in heart transplantation. J Heart Lung Transplant. 1992;11(2 Pt 1):431-4. PMID: 1571342. 123. Teuteberg JJ, Shullo M, Zomak R, McNamara D, McCurry K, Kormos RL. Aggressive steroidweaning after cardiac transplantation is possiblewithout theadditionalriskofsignificantrejection.ClinTransplant.2008;22(6):730- 7. doi: 10.1111/j.1399-0012.2008.00868.x. 124. Groetzner J, Meiser BM, Schirmer J, vScheidt W, Klauss V, Cremer P, et al. Tacrolimus or cyclosporine for immunosuppression after cardiac transplantation: which treatment reveals more side effects during long-term follow-up? Transplant Proc. 2001;33(1-2):1461-4. PMID: 11267373. 125. Meiser BM, Uberfuhr P, Fuchs A, Schmidt D, Pfeiffer M, Paulus D, et al. Single-center randomized trial comparing tacrolimus (FK506) and cyclosporine in the prevention of acutemyocardial rejection. J Heart Lung Transplant. 1998;17(8):782-8. PMID: 9730427. 126. Rinaldi M, Pellegrini C, Martinelli L, Goggi C, Gavazzi A, Campana C, et al. FK506 effectiveness in reducing acute rejection after heart transplantation: a prospective randomized study. J Heart Lung Transplant. 1997;16(10):1001-10. PMID: 9361242. 127. Reichart B, Meiser B, Viganò M, Rinaldi M, Martinelli L, Yacoub M, et al. European Multicenter Tacrolimus (FK506) Heart Pilot Study: one-year results--European Tacrolimus Multicenter Heart Study Group. J Heart Lung Transplant. 1998;17(8):775-81. PMID: 9730426. 128. Kobashigawa JA, Patel J, Furukawa H, Moriguchi JD, Yeatman L, Takemoto S, et al. Five-year results of a randomized, single-center study of tacrolimus vs microemulsion cyclosporine in heart transplant patients. J Heart Lung Transplant. 2006;25(4):434-9. doi: 10.1016/j.healun.2005.11.452. 129. Palmer SM, Baz MA, Sanders L, Miralles AP, Lawrence CM, Rea JB, et al. Results of a randomized, prospective, multicenter trial of mycophenolate mofetil versus azathioprine in the prevention of acute lung allograft rejection. Transplantation. 2001;71(12):1772-6. PMID: 11455257. 130. Kobashigawa J, Miller L, Renlund D, Mentzer R, Alderman E, Bourge R, et al. A randomized active-controlled trial of mycophenolate mofetil in heart transplant recipients. Mycophenolate Mofetil Investigators. Transplantation. 1998;66(4):507-15. PMID: 9734496. 284